Effect of Arginine on Serum-Levels of Human Growth-Hormone

Merimee, Thomas J.; Lillicrap, D.A.; Rabinowitz, D.

doi:10.1016/s0140-6736(65)90399-5

Cited by 203 publications

(58 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Another contributing factor may be the rising plasma levels of growth hormone observed after the ingestion of proteins (21) although significant changes (as presently measured) usually occur well after the first hour after the ingestion of the protein meals. The latter finding is consonant with our demonstration that intravenous administration of certain amino acids to normal subjects induces a release of immunodetectable growth hormone into the blood (22), a finding confirmed with respect to arginine by Merimee, Lillicrap, and Rabinowitz (23). Other metabolic and hormonal influences on glucose metabolism induced by ingestion of protein meals are not excluded.…”

Section: Discussionsupporting

confidence: 78%

Insulin secretion in response to protein ingestion.

Floyd¹,

Fajans²,

Conn³

et al. 1966

J. Clin. Invest.

192

View full text Add to dashboard Cite

W\e have reported previously that the oral or intravenous administration of the amino acid l-leucine to healthy subjects results in increases in plasma insulin and decreases in blood glucose and plasma free fatty acids (2, 3). After the administration of leucine to healthy subjects pretreated with either chlorpropamide or tolbutamide (2, 3), and also to some patients with functioning islet cell tumors of the pancreas (4), increments in plasma leucine caused increases in plasma insulin and decreases in blood glucose that were significantly greater than those observed in healthy subjects not pretreated with sulfonylurea drugs. We have also shown that increased release of insulin from the pancreatic beta cells is the mechanism by which leucine increases peripheral levels of insulin (5). We suggested that a rising plasma level of leucine is a physiologic stimulus for the release of insulin, and that the more pronounced sensitivity to leucine hypoglycemia produced experimentally by. administration of sulfonylureas and observed in some patients with idiopathic hypoglycemia or insulin-secreting tumors of the pancreas represents a great exaggeration of a normal physiologic phenomenon (6, 7).In an effort to determine the effect of leucine on insulin release under physiologic circumstances, protein meals rich in leucine were fed to healthy subjects, and the levels of plasma insulin, leucine, amino nitrogen, free fatty acids, and blood glucose

show abstract

Section: Discussionsupporting

confidence: 78%

Insulin secretion in response to protein ingestion.

Floyd¹,

Fajans²,

Conn³

et al. 1966

J. Clin. Invest.

192

View full text Add to dashboard Cite

show abstract

“…Furthermore, in the current study, for ASTs considered sufficient, the average serum growth hormone was above the standard 7.5 ng/mL threshold at, and only at, each of the three times that were determined typical. These times are, in our opinion, valid for the above reasons and also because they are in agreement with the typical peak times determined in several previous studies (3)(4)(5).…”

Section: Discussionsupporting

confidence: 93%

“…In our practice, as previously reported, the most common time for occurrence of the peak value was at 45 min after injection (3). This was similar to the peak times reported in the earliest descriptions of this test (4,5). Our group reported previously that, for the glucagon stimulation test (GST), most patients had peak levels of growth hormone 90 or 120 min after stimulation.…”

Section: Introductionsupporting

confidence: 87%

The arginine stimulation test: timing of peak is not a helpful parameter in the diagnosis of growth hormone deficiency

Gillis¹,

Granat

Strich³

2013

Journal of Pediatric Endocrinology and Metabolism

View full text Add to dashboard Cite

“…Increased K + levels were detected in 77% of patients in our study group, and 19% of patients had severe hyperkalaemia. These results are unexpectedly high, given that the changes in K + concentration induced by amino acid solution have been generally considered mild [10,12,26]. Rolleman et al assessed the effect of different preparations of amino acid solutions on kidney radioactivity uptake as well as on K + levels.…”

Section: Discussionmentioning

confidence: 99%

Effect of amino acid infusion on potassium serum levels in neuroendocrine tumour patients treated with targeted radiopeptide therapy

Giovacchini

Nicolas

Freidank

et al. 2011

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

Purpose Administration of positively charged amino acids has been introduced to reduce the nephrotoxicity of targeted radiopeptide therapy (TRT). However, the amino acid solution may have side effects, including hyperkalaemia. The aim of this study was to evaluate the frequency and the magnitude of hyperkalaemia in neuroendocrine tumour (NET) patients undergoing TRT. Methods Enrolled in the study were 31 patients with NET eligible for TRT with [ 90 Y-DOTA(0),Tyr(3)]octreotide ( 90 Y-DOTATOC). Their mean age was 54±14 years. Of these 31 patients, 21 (67%) were referred for the first treatment cycle, while 10 (33%) were referred for a subsequent therapy cycle. Patients were treated with therapeutic doses of 90 Y-DOTA-TOC ranging from 7,030 to 35,520 MBq. To inhibit tubular reabsorption of 90 Y-DOTATOC, 1 l of physiological saline solution containing 25 g of arginine hydrochloride and 25 g of lysine hydrochloride was given over 4 h starting 1 h before 90 Y-DOTATOC injection. All patients underwent a standard biochemical blood analysis at baseline, and 4 h and 24 h after the beginning of the amino acid infusion.Results ANOVA repeated measures showed a significant overall effect on K + levels over time (F=118.2, df=2, P< 0.0001). Mean serum levels of K + were 4.00±0.33 mmol/ l at baseline, 5.47 ± 0.57 mmol/l at 4 h, and 4.38 ± 0.63 mmol/l at 24 h after the beginning of the infusion. Post-hoc analysis showed that K + levels at 4 h were significantly (P<0.05) higher than at baseline. K + levels at 24 h were significantly (P<0.05) lower than at 4 h but they were still significantly (P<0.05) higher than K + levels at baseline. On a subject-by-subject basis, none of the 31 patients had increased K + levels at baseline. At 4 h, 24 of the 31 patients (77%) had K + levels above the normal range, and 6 patients (19%) experienced severe hyperkalaemia (K + ≥ 6 mmol/l). All patients with increased K + levels were clinically asymptomatic. At 24 h, only 4 patients (13%) had increased K + serum levels. The magnitude of the increase in K + levels between baseline and 4 h was relatively homogeneous over the whole group (1.41 ± 0.50 mmol/l) and it was not related (linear regression, P>0.05) to baseline K + levels. Intravenous administration of 40 mg furosemide 1 h after the beginning of the amino acid infusion did not have a significant effect on K + levels (P>0.05). No clinical characteristic was predictive for the increase in K + levels (chi-squared test, P > 0.05). Conclusion Hyperkalaemia is a frequent, potentially lifethreatening side effect of basic amino acid infusion during TRT. K + levels 4 h after the beginning of the infusion should be monitored in patients at risk of complications, such as those with heart disease and those with risk factors for nephrotoxicity.

show abstract

Effect of Arginine on Serum-Levels of Human Growth-Hormone

Cited by 203 publications

References 7 publications

Insulin secretion in response to protein ingestion.

Insulin secretion in response to protein ingestion.

The arginine stimulation test: timing of peak is not a helpful parameter in the diagnosis of growth hormone deficiency

Effect of amino acid infusion on potassium serum levels in neuroendocrine tumour patients treated with targeted radiopeptide therapy

Contact Info

Product

Resources

About